کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2589548 1562045 2015 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Is rivastigmine safe as pretreatment against nerve agents poisoning? A pharmacological, physiological and cognitive assessment in healthy young adult volunteers
ترجمه فارسی عنوان
آیا ریواستیگمین به عنوان پیشگیری از مسمومیت با عصب ها ایمن است؟ ارزیابی دارویی، فیزیولوژیکی و شناختی در داوطلبان جوان سالم جوان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری علوم محیط زیست بهداشت، سم شناسی و جهش زایی
چکیده انگلیسی


• Rivastigmine induces mild adverse reactions with high inter-personal variability.
• Rivastigmine impairs 2 cognitive functions (perceptual speed and dynamic response).
• Rivastigmine has non-linear and highly variable pharmacological profile.
• Rivastigmine use as pretreatment in an operational population is problematic.

Rivastigmine, a reversible cholinesterase inhibitor, approved as a remedy in Alzheimer's disease, was suggested as pretreatment against nerve agents poisoning. We evaluated the pharmacokinetic, pharmacodynamic, physiologic, cognitive and emotional effects of repeated rivastigmine in young healthy male adults, in a double blind, placebo controlled crossover trial. Three groups completed 3 treatment periods: 0, 1.5 and 3 mg twice a day, for a total of 5 intakes. Parameters monitored were: vital signs, ECG, laboratory tests, sialometry, visual accommodation, inspiratory peak flow, and cognitive function tests. Adverse reactions were mild. Peak blood levels and peak cholinesterase inhibition increased with repeated intakes, and high variability and non-linear pharmacokinetics were demonstrated. In addition, two cognitive functions were affected (perceptual speed and dynamic tracking). The complicated pharmacological profile and the high inter-personal variability limit the potential use of rivastigmine as pretreatment for war fighters and first responders.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: NeuroToxicology - Volume 49, July 2015, Pages 36–44
نویسندگان
, , , , , , , , ,